Pharma Pressreleases

This section covers the managerial aspects in the Pharma industry.

AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patients

Tuesday, January 29, 2019
PR Newswire

NORTH CHICAGO Ill Jan PRNewswire AbbVie NYSE ABBV a researchbased global biopharmaceutical company today announced that the US Food and Drug Administration FDA approved the use of IMBRUVICA ibrutinib in combination with obinutuzumab GAZYVA for adu...

Record Opioid Mortality in America Likely to Remain at Current Lethal Level for Years, U.S. News Analysis Finds

Tuesday, January 29, 2019
PR Newswire

WASHINGTON Jan PRNewswire Opioid mortality is five times higher than it was at the turn of the century and is likely to remain at the same level or rise even higher for years to come according to an

First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington\'s Disease

Tuesday, January 29, 2019
PR Newswire

CARLSBAD Calif Jan PRNewswire Ionis Pharmaceuticals Inc NASDAQ IONS the leader in antisense therapeutics today announced that its partner Roche also known as Genentech in the United States has enrolled the first patient in a pivotal study of RG IO...

Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™

Tuesday, January 29, 2019
PR Newswire

TORRANCE Calif Jan PRNewswire Emmaus Life Sciences IncEmmaus a leader in sickle cell disease treatment announced today that it will provide financial assistance to help eligible patients afford their monthly copayment for Endari Lglutamine oral po...

Completion of Manufacturing of Clinical Grade FasL Enables Cellect to Expedite U.S. Clinical Programs into Multiple Studies

Tuesday, January 29, 2019
PR Newswire

TEL AVIV Israel January PRNewswire Cellect Biotechnology Ltd NASDAQ APOP a developer of a novel stem cell production technology today announced it has concluded the scaleup development and manufacturing of clinical grade FasL in collaboration with...

U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

Tuesday, January 29, 2019
PR Newswire

HORSHAM Pa Jan PRNewswire The Janssen Pharmaceutical Companies of Johnson Johnson announced today the US Food and Drug Administration FDA approval of IMBRUVICA ibrutinib in combination with obinutuzumab in treatmentnave patients with chronic lymph...

GeneNews Publishes Data on ColonSentry® in Colorectal Cancer Risk Assessment

Tuesday, January 29, 2019
PR Newswire

Study demonstrates validity of bloodbased biomarker test as an adjunct method to colon cancer screening tests in noncompliant patient populations TORONTO Jan PRNewswire GeneNews Limited TSXGEN GeneNews or the Company today announced it has publis...

Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)

Tuesday, January 29, 2019
PR Newswire

OLDWICK NJ Jan PRNewswire Provention Bio Inc NasdaqPRVB a clinicalstage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immunemediated diseases announced today that it has received a Notice...

Histogen Appoints Richard Pascoe as Chairman and Chief Executive Officer

Tuesday, January 29, 2019
PR Newswire

SAN DIEGO Jan PRNewswire Histogen Inc a regenerative medicine company focused on stimulating the bodys stem cells to regenerate tissues and restore youthful function today announced that the Companys Board of Directors has appointed Richard Pascoe...

First-In-Human Case Using Biostage\'s Bioengineered Esophageal Implant is Presented at Major Surgical Meeting

Tuesday, January 29, 2019
PR Newswire

HOLLISTON Mass Jan PRNewswire Dennis Wigle MD PhD chair of thoracic surgery at Mayo Clinic in Rochester Minnesota speaking at the Society of Thoracic Surgeons TechCon meeting on January announced for the first t